Oncovita SAS, of Paris, said it entered a licensing agreement with Institut Pasteur, granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform. Financial terms of the agreement were not disclosed.

Morphic Holding Inc., of Waltham, Mass., said it closed its IPO of 6.9 million common shares, including 900,000 shares sold for the full exercise of overallotments, at $15 apiece to raise $103.5 million. 

Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., appointed Megan Sniecinski chief business officer.

CNS Pharmaceuticals Inc., of Houston, filed an S-1 with the SEC for a proposed IPO to raise about $10 million by offering 2.1 million shares priced at $4 to $5 per share. Founded in 2017, CNS Pharmaceuticals is developing therapies for brain cancer and other central nervous system tumors. It is seeking a listing on Nasdaq under the ticker CNSP.

The FDA Monday released two draft guidances on the content and format of specific sections in prescription drug labeling. 

Shares of San Diego-based Atyr Pharma Inc. (NASDAQ:LIFE) rose 6.3% to $5.45 on the company's first full day of trading following a 1-for-14 reverse split of its common stock that helped the company regain compliance with the Nasdaq minimum bid price requirement.